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ABSTRACT
Introduction The COVID-19 pandemic has been 
characterised by significant in- hospital virus transmission 
and deaths among healthcare workers. Sources of in- 
hospital transmission are not fully understood, with special 
precautions currently reserved for procedures previously 
shown to generate aerosols (particles <5 μm). Pleural 
procedures are not currently considered AGPs (Aerosol 
Generating Procedures), reflecting a lack of data in this 
area.
Methods An underwater seal chest drain bottle (R54500, 
Rocket Medical UK) was set up inside a 60- litre plastic 
box and connected via an airtight conduit to a medical 
air supply. A multichannel particle counter (TSI Aerotrak 
9310 Aerosol Monitor) was placed inside the box, allowing 
measurement of particle count/cubic foot (pc/ft3) within 
six channel sizes: 0.3–0.5, 0.5–1, 1–3, 3–5, 5–10 and 
>10 μm. Stabilised particle counts at 1, 3 and 5 L/min 
were compared by Wilcoxon signed rank test; p values 
were Bonferroni- adjusted. Measurements were repeated 
with a simple anti- viral filter, designed using repurposed 
materials by the study team, attached to the drain bottle. 
The pressure within the bottle was measured to assess 
any effect of the filter on bottle function.
Results Aerosol emissions increased with increasing air 
flow, with the largest increase observed in smaller particles 
(0.3–3 μm). Concentration of the smallest particles (0.3–
0.5 μm) increased from background levels by 700, 1400 
and 2500 pc/ft3 at 1, 3 and 5 L/min, respectively. However, 
dispersion of particles of all sizes was effectively prevented 
by use of the viral filter at all flow rates. Use of the filter 
was associated with a maximum pressure rise of 0.3 cm 
H2O after 24 hours of flow at 5 L/min, suggesting minimal 
impact on drain function.
Conclusion A bubbling chest drain is a source of 
aerosolised particles, but emission can be prevented using 
a simple anti- viral filter. These data should be considered 
when designing measures to reduce in- hospital spread of 
SARS- CoV-2.
INTRODUCTION
Previous coronavirus epidemics were char-
acterised by high infection rates in health-
care workers (HCWs) and ‘super- spreading’ 
events within hospitals. Despite implementa-
tion of WHO guidance designed to reduce 
in- hospital spread,1 nosocomial and HCW 
infection have remained prominent features 
of the current COVID-19 pandemic, with 
43.5% of UK HCWs becoming seropositive 
over a 1- month period in one recent study.2 
Better understanding of in- hospital infec-
tion sources is therefore urgently needed. 
Pleural procedures are not currently consid-
ered aerosol- generating by the WHO,1 and 
special precautions to mitigate against viral 
transmission and/or to protect HCWs are 
not currently recommended. However, this 
is based on the absence of any prior data 
regarding the aerosol- generating potential 
of a chest drain (where an aerosol is defined 
as a particle smaller than 5 μm) rather than 
a robust understanding of the level of risk 
involved. Recent studies report detection of 
SARS- CoV-2 in COVID-19- associated pleural 
effusion3 4 and ‘super- spreading’ events linked 
to chest drain use. The latter includes a cohort 
of 25 Chinese patients (including 12 HCWs) 
infected from a single index case who under-
went elective lobectomy with undetected 
SARS- CoV-2 infection.5 This has prompted 
expert bodies, including the British Thoracic 
Society (BTS)6 and the American Association 
Key messages
 ► The objectives of this study were to determine 
whether a bubbling chest drain is aerosol- generating 
and the efficacy of a simple anti- viral filter.
 ► A bubbling chest drain is a source of aerosolised 
particles, but emission can be prevented using a 
simple anti- viral filter.
 ► The WHO and expert groups, including the British 
Thoracic Society, disagree on the risks posed by 
pleural procedures during the COVID-19 pandemic. 
This reflects the absence of any prior data on wheth-
er pleural procedures generate aerosols and merit 
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for the Surgery of Trauma (AAST)7 to recommend risk 
mitigation of some form until the level of risk involved is 
more clearly understood. Risk mitigation options include 
connection of all patients to wall suction, use of a digital 
chest drain system or use of a bespoke anti- viral filter 
attached to a standard chest drain bottle.6 The objectives 
of this study were to determine (a) whether a bubbling 
chest drain is aerosol- generating and (b) the efficacy 
of an anti- viral filter developed in- house. We chose this 
option since wall suction greatly restricts patient mobility 
and digital drainage systems do not contain suitable viral 
filters for exit gases.
METHODS
The experimental set- up used is shown in figure 1. An 
underwater seal chest drain bottle (R54500, Rocket 
Medical UK) was set up according to the manufacturer’s 
instructions and placed inside a sealable 60- litre plastic 
box. The drain tubing (Ref R54502) was attached to a 
medical air cylinder via an airtight conduit in the wall of 
the box. A multichannel particle counter (TSI Aerotrak 
9310 Aerosol Monitor) was placed inside the box, allowing 
measurement of particle count/cubic foot (pc/ft3) within 
six channel sizes: 0.3–0.5, 0.5–1, 1–3, 3–5, 5–10 and >10 
μm. Stabilised particle counts at different flow rates 
(without and with the filter attached) were compared by 
Wilcoxon signed rank test (R V.4.0.2 (Vienna, Austria)); 
p values were adjusted for multiple comparisons by the 
Bonferroni method. For filter comparisons, relative 
differences, normalised to without- filter readings, were 
assessed. Ethical approval was not required.
Viral filter
A COVID-19 anti- viral filter device was designed by 
the study team and manufactured using repurposed 
equipment (see figure 1, and online supplemental for 
detailed instructions for use). The completed assembly 
was comprised of a heat and moisture exchange filter 
normally used on a ventilator circuit (Teleflex Humid- 
Vent Filter Compact, 19 402T), a 5 cm section of standard 
chest drain tubing (Rocket Medical R54502) and the 
proximal adapter from a size 8 endotracheal tube 
(Portex 100/199/080). The safe functioning of the filter 
was assessed within a Failure Mode and Effects Analysis 
framework (BS EN ISO 14971:2012: application of risk 
management to medical devices). This included demon-
stration that over 24 hours of continuous flow at 5 L/
min, the pressure within the bottle rose by no more than 
0.3 cm H2O, suggesting the filter has minimal impact on 
drain function.
Aerosol measurement
Particle concentrations in the air surrounding the chest 
drain were initially sampled without the filter attached. 
Baseline conditions were first sampled for 20 min. 
Medical air was then pumped through the circuit for 
20 min at 1 L/min, before being switched off, allowing 
baseline conditions to re- stabilise over a further 20 min. 
After each 60 min experiment, the box was opened, 
measurements were recorded and the unit resealed. The 
experiment was repeated using flow rates of 3 and 5 L/
min, and then all three experiments were repeated with 
the filter attached (see figure 1B). Each experiment was 
conducted on a single occasion.
RESULTS
Particle concentrations measured in each channel at 1, 3 
and 5 L/min, without the filter attached are summarised in 
figure 2, absolute values reported in online supplemental 
table 1. Particle emissions increased with increasing air 
flow, with the largest increase observed in the smaller 
particles (0.3–3 μm). Concentration of the smallest parti-
cles (0.3–0.5 μm) increased from background levels by 
Figure 1 (A) Experimental set- up including the Aerotrak 
9310 (to the left of the images) and the underwater seal 
chest drain bottle (Rocket R54500, to the right of the 
images) inside the sealed 60- litre plastic box. Standard 
chest drain tubing (R54502) has been used to connect 
the chest drain bottle to a medical air cylinder. (B) The 
assembled COVID-19 anti- viral filter, comprised of a heat 
and moisture exchange (HME) filter (Teleflex Humid- Vent 
Filter Compact, 19 402T), attached via a 5 cm section of 
standard chest drain tubing (Rocket Medical R54502) 
and the proximal adapter from a size 8 endotracheal tube 
(Portex 100/199/080). Detailed instructions for use are 
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700, 1400 and 2500 pc/ft3 at 1, 3 and 5 L/min, respec-
tively (see figure 2). Particle counts (pc/ft3) significantly 
increased (based on Bonferroni- adjusted p<0.00086) at 
all flow rates and in all channel sizes, except at 1 L/min 
in the 5–10 μm channel (adjusted p value not significant 
at 0.02).
Particle concentrations measured in each channel at 1, 
3 and 5 L/min, with the filter attached are summarised in 
figure 3, absolute values reported in online supplemental 
table 1. Particle counts (pc/ft3) were notably lower in all 
channels compared with without- filter measurements. 
Counts of the smallest particles significantly reduced 
between baseline and initiation of air flow (based on 
Bonferroni- adjusted p<0.00086) at 1 L/min (0.3–0.5 
μm only), 3 and 5 L/min (0.3–0.5, 0.5–1, 1–3 μm chan-
nels), likely reflecting dilution of background aerosols 
by filtered air. With the filter added, normalised particle 
count differences were significantly lower (p<0.00086) in 
the smaller channels (0.3–0.5, 0.5–1, 1–3, 3–5 μm) at all 
flow rates, compared with without- filter values.
DISCUSSION
The data reported here indicate that particles in the 
aerosol range (<5 μm) are generated by a bubbling chest 
drain at continuous flow rates of at least 1 L/min. Aerosol 
emissions increased with increasing air flow, simulating 
a high- volume air- leak, as might be expected following 
thoracic surgery, in mechanically ventilated patients or 
patients with a large spontaneous alveolar- pleural fistula 
complicating bullous lung disease. These data were 
recorded as part of a comprehensive risk assessment 
process, which demonstrated no significant limitation of 
air flow through the chest drain circuit with the filter in 
situ.
Aerosols are typically generated by air moving across the 
surface of a liquid, with increasing air forces generating 
smaller particles.1 This is consistent with the observations 
reported here in that unfiltered emissions of the smallest 
particles (0.3–0.5 μm) increased progressively from 1 to 
3 to 5 L/min. Our findings are also concordant with a 
recent study reported by Akhtar et al, in which a similar 
anti- viral filter was evaluated and produced a qualitative 
Figure 2 Particle concentrations, as measured by the 
TSI Aerotrak 9310 Aerosol Monitor, while air was bubbled 
through a standard underwater seal chest drain (Rocket 
R54500) without a filter at flow rates of (A) 1 L/min, (B) 3 L/
min and (C) 5 L/min. The red arrows on each graph show 
when the air flow was turned on and then turned off again.
Figure 3 Particle concentrations, as measured by the 
TSI Aerotrak 9310 Aerosol Monitor, while air was bubbled 
through a standard underwater seal chest drain (Rocket 
R54500) with a filter at flow rates of (A) 1 L/min, (B) 3 L/min 
and (C) 5 L/min. The red arrows on each graph show when 
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reduction in droplet emissions. However, droplet size, 
and therefore aerosolisation potential were not exam-
ined.8 These data support risk mitigation in patients with 
suspected or proven COVID-19, as recommended by the 
BTS6 and the AAST.7 However, the absolute risk involved 
remains uncertain and the experimental set- up used 
cannot be considered exactly equivalent to a bubbling 
drain in a clinical setting. Pleural effusion and pneumo-
thorax appear uncommon complications of COVID-19 
(occurring in ~5% and ~1% of cases, respectively6 8) and 
an aerosol- generating chest drain can clearly only be an 
infection risk if SARS- CoV-2 is (a) present in any effusion 
drained (which may be of minimal volume in patients 
with pneumothorax and major air- leaks) and (b) remains 
viable long enough to be aerosolised. Lescure et al3 and 
Mei et al4 have recently reported cases of SARS- CoV-2 posi-
tive effusions, but in these cases air- leak was not reported 
as a significant component, and larger studies are needed 
to define the prevalence and risks of unfiltered air- leaks 
in COVID-19 more clearly. In a recent postmortem 
series, Schaller et al reported that 50% of patients with 
fatal COVID-19 had associated pleural effusion, of which 
50% were PCR positive.9 The risk of nosocomial transmis-
sion via an unfiltered air- leak may therefore be highest 
in patients with the most advanced disease in the event 
of a secondary pneumothorax complicating positive 
pressure ventilation. With regard to viability over time, 
SARS- CoV-2 has been shown to remain viable in aerosols 
for several hours and on surfaces for several days,10 so 
could probably persist in a chest drain bottle for suffi-
ciently long to be an infection risk.
The experiments reported here were carried out in 
a controlled environment with minimal background 
environmental disturbances. It is therefore unknown 
how normal background activities (eg, staff proximity, 
the opening and closing of doors), which can affect the 
rate of aerosols resuspension on surfaces, would affect 
concentrations in a clinical setting. Given that our data 
were recorded at flow rates of 1, 3 and 5 L/min, it should 
also be acknowledged that the particle emission profile 
of smaller volume air- leaks cannot be directly concluded 
from our data. Nevertheless, it appears clear that a 
bubbling chest drain is a potential source of aerosolised 
particles, and that dispersion can be prevented using a 
simple anti- viral filter. These data should be considered 
when designing measures to reduce in- hospital spread of 
SARS- CoV-2.
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COVID-19 Chest Drain Filter Modification 
Instructions for Use 
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1. Intended Use 
To reduce the risk of viral particle expulsion from a R54500 Rocket Chest Drainage Bottle in the 
management of pneumothorax in patients suspected or confirmed infected with COVID-19. 
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2. Preparing the Filter Connector Assembly 
 
Rocket Chest Drain 
Tubing Set, Ref R54502 
 
8.0mm Portex Tracheal 










2.1. On a sterile tray, remove the Rocket Chest Drain Tubing Set from its packaging. 
2.2. Using the Sterile Scissors or Scalpel and the Sterile Ruler, cut a 5cm section of tubing from 
the end of the Tubing Set.   
2.3. Verify that the cut length of tubing is between 4.5-5.5cm (if otherwise, repeat step 2.2) 
then dispose of the remainder of the Tubing Set. 
2.4. Remove the 8.0mm Portex Tracheal Tube from its packaging. 
2.5. Remove the blue connector piece and dispose of the rest of the Tracheal Tube. 
2.6. Attach the cut piece of tube to the blue connector.  Ensure the tube is pushed to the end of 













Figure 2A: Push the cut tube onto 
the blue connector so that there is 
no more than a 5.0mm gap between 
the end of the tube and the 
connector. 
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6. Important Information 
6.1. Replace the filter after 24 hours of use (See Replacing the Filter Section 4). 
6.2. Wear appropriate PPE for each procedure in this document as per local guidelines. 
6.3. Regularly check that the connections between the Filter, Filter Connector Assembly and 
Nozzle remain tight and secure, and record on the chest drain chart. 
6.4. Ensure that the cap on the Teleflex Humid-Vent Filter Compact remains closed at all times. 
6.5.  Take care to minimise swaying or knocking of the Bottle. 
6.6. Regularly check that the Filter and tube are not visibly kinked or occluded.  If kinking or 
occlusion is detected, replace the Filter Connector Assembly and/or Filter as necessary.     
6.7. If the Filter comes into contact with liquid, or appears to be visibly saturated with liquid, 
the Filter and Filter Connector Assembly should be replaced.  
7. Warnings 
7.1. For use by a medical professional only. 
7.2. Only use for the Intended Use as specified in Section 1. 
7.3. The device is manufactured under the MDR Health Institute Exemption and is not approved 
for use outside NHS Greater Glasgow and Clyde. 
7.4. All parts are single use. 
7.5. This modification is not designed to prevent the release of viral particles via the pressure 
release valve. 
7.6. Follow local guidelines for infection control and safe disposal of parts. 
 
8. Incident Reporting 
Any serious incident that has occurred in relation to this device should be logged in Datix and 
reported to the manufacturer (below). 
 
9. Manufacturer Details 
Medical Devices Unit, NHS Greater Glasgow and Clyde  
West Glasgow Ambulatory Care Hospital  
Dalnair Street  
Yorkhill  
Glasgow 





The manufacturers welcome feedback 
on this device modification.  To provide 
feedback, please visit the website 
below and complete the COVID-19 




BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Resp Res
 doi: 10.1136/bmjresp-2020-000710:e000710. 7 2020;BMJ Open Resp Res, et al. Duffy C
Supplementary Table 1. Comparison between ‘baseline’ and ‘functioning’ particle 
concentrations (particle count/cubic foot (pc/ft3)). ‘Functioning’ concentrations were 
measured at 1, 3 and 5L/min air flow (+/- an anti-viral filter). Values are reported as medians 
(standard error (SE)) and comparisons are by Wilcoxon signed rank tests, with p-values 
adjusted for multiple comparisons (significant values in bold). NA: Not available as both 




















0.3-0.5 µm 185 (6.11) 833 (8.22) <0.00086 22 (1.42) 13 (0.60) <0.00086 
0.5-1 µm 27 (1.52) 230 (3.70) <0.00086 3 (0.25) 2 (0.26) 0.1598 
1-3 µm 5 (0.54) 46 (1.91) <0.00086 0 (0.09) 0 (0.11) 0.08314 
3-5 µm 27 (1.53) 230 (3.92) <0.00086 3 (0.25) 2 (0.26) 0.07186 
5-10 µm 0 (0) 0 (0.07) 0.02627 0 (0.03) 0 (0) 1 
>10 µm 0 (0) 0 (0) NA 0 (0.03) 0 (0) 1 
3L/min 
















0.3-0.5 µm 170 (11.45) 1417 (15.73) <0.00086 119 (7.84) 15 (0.91) <0.00086 
0.5-1 µm 38 (1.76) 546 (5.11) <0.00086 13 (0.81) 3 (0.36) <0.00086 
1-3 µm 6 (0.53) 209 (3.77) <0.00086 1 (0.25) 0 (0.11) <0.00086 
3-5 µm 38 (1.85) 546 (5.15) <0.00086 13 (0.81) 3 (0.38) 1 
5-10 µm 0 (0.03) 1 (0.20) <0.00086 0 (0) 0 (0) NA 
>10 µm 0 (0) 0 (0) NA 0 (0) 0 (0) NA 
5L/min 
















0.3-0.5 µm 216 (8.25) 2692 (37.57) <0.00086 144 (6.41) 12 (0.75) <0.00086 
0.5-1 µm 20 (0.82) 1070 (10.00) <0.00086 14 (0.80) 3 (0.26) <0.00086 
1-3 µm 3 (0.25) 436 (6.20) <0.00086 2 (0.22) 0 (0.08) <0.00086 
3-5 µm 20 (1.00) 1070 (10.34) <0.00086 14 (0.90) 3 (0.26) 1 
5-10 µm 0 (0.05) 5 (0.38) <0.00086 0 (0) 0 (0.03) 1 
>10 µm 0 (0) 1 (0.14) <0.00086 0 (0) 0 (0) NA 
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